Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 8:25 pm Sale |
2024-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
Forward Ventures V, LP | 847,600 4.300% |
-1,719,922 (-66.99%) |
Filing History |
| 2024-11-14 4:33 pm Sale |
2024-09-30 | 13G | Viracta Therapeutics, Inc. VIRX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-3,833,785 (Position Closed) |
Filing History |
| 2024-02-13 9:04 pm Sale |
2023-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
Forward Ventures V, LP | 2,567,522 6.650% |
-97,268 (-3.65%) |
Filing History |
| 2023-02-13 5:53 pm Purchase |
2022-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
BIOTECHNOLOGY VALUE FUND L P | 3,833,785 9.980% |
102,041 (+2.73%) |
Filing History |
| 2023-01-10 5:21 pm Unchanged |
2022-06-08 | 13D | Viracta Therapeutics, Inc. VIRX |
Schindel Yair Chaim | 7,392,237 19.350% |
0 (Unchanged) |
Filing History |
| 2022-07-08 4:56 pm Sale |
2022-06-30 | 13G | Viracta Therapeutics, Inc. VIRX |
BLACKROCK INC BLK |
542,431 1.400% |
-1,826,487 (-77.10%) |
Filing History |
| 2022-02-15 1:48 pm Purchase |
2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
LYTTON LAURENCE W | 255,876 0.700% |
255,876 (New Position) |
Filing History |
| 2022-02-14 1:33 pm Purchase |
2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
BIOTECHNOLOGY VALUE FUND L P | 3,731,744 9.900% |
3,731,744 (New Position) |
Filing History |
| 2022-02-14 12:14 pm Purchase |
2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
Aisling Capital IV LP | 288,571 0.770% |
288,571 (New Position) |
Filing History |
| 2022-02-09 5:24 pm Purchase |
2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
Forward Ventures V, LP | 2,664,790 7.140% |
42,516 (+1.62%) |
Filing History |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
BLACKROCK INC BLK |
2,368,918 6.300% |
2,368,918 (New Position) |
Filing History |
| 2021-03-10 9:40 pm Unchanged |
2020-08-11 | 13D | Viracta Therapeutics, Inc. VIRX |
New Enterprise Associates 12 Limited Partnership | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2021-03-08 5:05 pm Purchase |
2021-02-25 | 13G | Viracta Therapeutics, Inc. VIRX |
Forward Ventures V, LP | 2,622,274 7.090% |
2,622,274 (New Position) |
Filing History |
| 2021-03-05 1:30 pm Purchase |
2021-02-25 | 13G | Viracta Therapeutics, Inc. VIRX |
LVP LIFE SCIENCE VENTURES III L.P. | 3,124,094 8.440% |
3,124,094 (New Position) |
Filing History |
| 2021-03-02 06:14 am Purchase |
2021-02-24 | 13D | Viracta Therapeutics, Inc. VIRX |
Schindel Yair Chaim | 7,392,237 19.980% |
7,392,237 (New Position) |
Filing History |
| 2021-02-16 3:50 pm Unchanged |
2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS |
CAXTON CORP | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2021-02-16 11:06 am Sale |
2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS |
Ayrton Capital LLC | 0 0.000% |
-10,869,565 (Position Closed) |
Filing History |
| 2021-02-16 09:50 am Unchanged |
2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS |
CVI Investments, Inc. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2021-02-16 06:24 am Unchanged |
2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS |
Nantahala Capital Management, LLC | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2021-02-12 6:47 pm Purchase |
2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS |
BIOTECHNOLOGY VALUE FUND L P | 1,814,308 9.980% |
1,814,308 (New Position) |
Filing History |